Interpace Biosciences Balance Sheet Health
Financial Health criteria checks 2/6
Interpace Biosciences has a total shareholder equity of $-14.6M and total debt of $8.8M, which brings its debt-to-equity ratio to -60.5%. Its total assets and total liabilities are $12.1M and $26.7M respectively. Interpace Biosciences's EBIT is $3.0M making its interest coverage ratio 3.1. It has cash and short-term investments of $2.8M.
Key information
-60.5%
Debt to equity ratio
US$8.84m
Debt
| Interest coverage ratio | 3.1x |
| Cash | US$2.81m |
| Equity | -US$14.60m |
| Total liabilities | US$26.75m |
| Total assets | US$12.14m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: IDXG has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: IDXG's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: IDXG's debt is well covered by operating cash flow (29.4%).
Interest Coverage: IDXG's interest payments on its debt are well covered by EBIT (3.1x coverage).